# US 2017/0246280 A1 · Modified Immunization Vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0246280 A1
- Document ID: US20170246280A1
- Status: Published application
- Kind: A1
- Application number: 15/289,297
- Filed: 2016-10-10
- Published: 2017-08-31
- Earliest claimed: 2009-04-30
- Assignees: Arizona Board of Regents, a body corporate of the State of Arizona, acting for and on behalf of Ariz; Consejo Superior De Investgaciones Cientrificas; IPPOX Foundation
- Inventors: Giuseppe Pantaleo; Thierry Calandra; Alexandre Harari; Thierry Roger; Mario Esteban; Bertram Jacobs; Karen Kibler; Cornelius Melief; Rafick-Pierre Sekaly; Elias Haddad; James Tartaglia
- Web page: https://patentgrep.com/patent/US20170246280A1

## CPC

- C12N 15/86: Viral vectors
- A61K 39/275: Poxviridae, e.g. avipoxvirus
- A61K 39/295: Polyvalent viral antigens (vaccinia virus or variola virus A61K39/285); Mixtures of viral and bacterial antigens
- A61P 37/02: Immunomodulators
- A61K 39/12: Viral antigens
- A61K 49/00: Preparations for testing in vivo
- A61K 2039/5256: {expressing foreign proteins}
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A recombinant NYVAC vector encoding at least one polypeptide selected from the group consisting of C1L (SEQ ID NO. 5), C2L (SEQ ID NO. 7), C3L (SEQ ID NO. 9), C4L (SEQ ID NO. 11), C5L (SEQ ID NO. 13), C6L (SEQ ID NO. 15), C7L (SEQ ID NO. 17), N1L (SEQ ID NO. 19), N2L (SEQ ID NO. 21), M1L (SEQ ID NO. 23), M2L (SEQ ID NO. 25) and K1L (SEQ ID NO. 27).

### Claim 36 (depends on 35)

The recombinant NYVAC vector of claim 35 wherein the vector genome encodes two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve of the polypeptides.

### Claim 37 (depends on 35)

The recombinant NYVAC vector of claim 35 wherein the polypeptides are C7L (SEQ ID NO. 17) and K1L (SEQ ID NO. 27).

### Claim 38 (depends on 35)

The recombinant NYVAC vector of claim 35, further comprising a polynucleotide encoding Ambystoma tigrinum virus Eukaryotic Translation Initiation Factor (ATV eIF2αH) (SEQ ID NO. 29).

### Claim 39 (depends on 35)

The recombinant NYVAC vector of claim 35 wherein the immunogen directs an immune response against an antigen selected from the group consisting of a viral target antigen, a bacterial target antigen, a parasitic target antigen, or a tumor target antigen.

### Claim 40 (depends on 39)

The recombinant NYVAC vector of claim 39 wherein the viral target antigen is derived from a virus selected from the group consisting of an adenovirus, herpes virus, epstein-barr virus, human cytomegalovirus, varicella-zoster virus, poxvirus, parvovirus, papillomavirus, reovirus, picornavirus, coxsackie virus, hepatitis A virus, poliovirus, togavirus, rubella virus, flavivirus, hepatitis C virus, yellow fever virus, dengue virus, west Nile virus, orthomyxovirus, influenza virus, rhabdovirus, paramyxovirus, measles virus, mumps virus, parainfluenza virus, respiratory syncytial virus, rhabdovirus, rabies virus, retrovirus, human immunodeficiency virus (HIV), hepadnavirus, and hepatitis B virus.

### Claim 41 (depends on 40)

The recombinant NYVAC vector of claim 40 wherein the virus is human immunodeficiency virus (HIV).

### Claim 42 (depends on 41)

The recombinant NYVAC vector of claim 41 wherein the immunogen is encoded by the genome of HIV-1 intersubtype (C/B′).

### Claim 43 (depends on 41)

The recombinant NYVAC vector of claim 41 wherein the immunogen is selected from the group consisting of Env, Gag, Nef, and Pol.

### Claim 44 (depends on 43)

The recombinant NYVAC vector of claim 43 wherein the immunogen is provided by a GAG-POL-NEF fusion protein.

### Claim 45 (depends on 41)

The recombinant NYVAC vector of claim 41 wherein the immunogen has the amino acid sequence selected from the group consisting of ENV, GAG, POL, NEF, VGNLWVTVYYGVPVW (SEQ ID NO. 56), WVTVYYGVPVWKGAT (SEQ NO. 57), GATTTLFCASDAKAY (SEQ ID NO. 58), TTLFCASDAKAYDTE (SEQ ID NO. 59), THACVPADPNPQEMV (SEQ ID NO. 60), ENVTENFNMWKNEMV (SEQ ID NO. 61), ENFNMWKNEMVNQMQ (SEQ ID NO. 62), EMVNQMQEDVISLWD (SEQ ID NO. 63), CVKLTPLCVTLECRN (SEQ ID NO. 64), NCSFNATTVVTRDRKQ (SEQ ID NO. 65), NATTVVRDRKQTVYA (SEQ ID NO. 66), VYALFYRLDIVPLTK (SEQ ID NO. 67), FYRLDIVPLTKKNYS (SEQ ID NO. 68), INCNTSAITQACPKV (SEQ ID NO. 69), PKVTFDPIPIHYCTP (SEQ ID NO. 70), FDPIPIHYCTPAGYA (SEQ ID NO. 71), TGDIIGDIRQAHCNI (SEQ ID NO. 72), SSSIITIPCRIKQII (SEQ ID NO. 73), ITIPCRIKQIINMWQ (SEQ ID NO. 74), CRIKQIINMWQEVGR (SEQ ID NO. 75), VGRAMYAPPIKGNIT (SEQ ID NO. 76), MYAPPIKGNITCKSN (SEQ ID NO. 77), PIKGNITCKSNITGL (SEQ ID NO. 78), ETFRPGGGDMRNNWR (SEQ ID NO. 79), ELYKYKVVEIKPLGV (SEQ ID NO. 80), YKVVEIKPLGVAPTT (SEQ ID NO. 81), EIKPLGVAPTTTKRR (SEQ ID NO. 82), LGVAPTTTKRRVVER (SEQ ID NO. 83), and YSENSSEYY (SEQ ID NO. 84).

### Claim 46 (depends on 39)

The recombinant NYVAC vector of claim 39 wherein the bacterial target antigen is derived from a bacterial organism selected from the group consisting of Bacillus anthracis, Bordetella pertussis, Borrelia burgdorferi, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diptheriae, Enterococcus faecalis, enterococcus faecum, Escherichia coli, Francisella tularensis, Haemophilia influenza, Helicobacter pylori, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhea, Neisseria meningitidis, Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella typhi, Salmonella typhimurium, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, coagulase negative Staphylococcus, Streplococcus agalactiae, Streplococcus pneumoniae, Streptococcus pyrogenes, Treponema pallidum, cholerae, and Yersinia pestis.

### Claim 47 (depends on 39)

The NYVAC recombinant vector of claim 39 wherein the parasite target antigen is derived from an organism selected from the group consisting of Ancylostoma duodenale, Anisakis spp., Ascaris lumbricoides, Balantidium coli, Cestoda spp., Cimicidae spp., Clonorchis sinensis, Dicrocoelium dendriticum, Dicrocoelium hospes, Diphyllobothrium latum, Dracunculus spp., Echinococcus granulosus, Echinococcus multilocularis, Entamoeba histolytica, Enterobius vermicularis, Fasciola hepatica, Fasciola magna, Fasciola gigantim, Fasciola jacksoni, Fasciolopsis buski, Giardia lamblia, Gnathostoma spp., Hymenolepis nana, Hymenolepis diminuta, Leishmania spp., Loa loa, Metorchis conjunctus, Metorchis albidus, Necator americanus, Oestroidea spp., Onchocercidae spp., Opisthorchis viverrini, Opisthorchis felineus, Opisthorchis guayaquilensis, Opisthorchis noverca, Plasmodium falciparum, Protofasciola robusta, Parafasciolopsis fasciomorphae, Paragonimus westermani, Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma haematobium, Spirometra erinaceieuropaei, Strongyloides stercoralis, Taenia saginata, Taenia solium, Thxocara canis, Toxocara cati, Toxoplasma gondii, Trichobilharzia regenti, Trichinella spiralis, Trichuris trichiura, Trombiculidae spp., Trypanosoma spp., Tunga penetrans, and Wuchereria bancrofti.

### Claim 48 (depends on 39)

The recombinant NYVAC vector of claim 39 wherein the tumor target antigen is selected from the group consisting of a gp100 MART-1/Melan A, gp75 (TRP-1), tyrosinase, NY-ESO-1, melanoma proteoglycan a MAGE family antigen, a BAGE family antigen, a GAGE family antigen, a RAGE family antigens, N-acetylglucosaminyltransferase-V, p15, β-catenin, MUM-1, cyclin dependent kinase-4 (CDK4), p21-ras, BCR-abl, p53, p185 HER2/neu, epidermal growth factor receptor (EGFR), carcinoembryonic antigen (CEA), a carcinoma-associated mutated mucin, MUC-1, prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), KSA, kinesin 2, HIP-55, TGFβ-1 anti-apoptotic factor, tumor protein D52, H1FT, NY-BR-1, NY-BR-62, NY-BR-75, NY-BR-85, NY-BR-87, NY-BR-96, and a pancreatic cancer antigen.

### Claim 49 (depends on 1)

A composition comprising a recombinant NYVAC vector of claim 1 and a pharmaceutically acceptable carrier.

### Claim 50 (depends on 49)

A method of immunizing a host against a viral target antigen, a bacterial target antigen, a parasitic target antigen, or a tumor target antigen comprising administering the composition of claim 49 to the host.

### Claim 51 (depends on 50)

The method of claim 50 wherein the immune response is protective.

### Claim 52 (depends on 50)

The method of claim 50 wherein the host is a human being.

### Claim 53 (depends on 51)

The method of claim 51 wherein the host is a human being.
